Kyle Staller1, Mary K Townsend2, Hamed Khalili3, Raaj Mehta3, Francine Grodstein2, William E Whitehead4, Catherine A Matthews5, Braden Kuo6, Andrew T Chan3. 1. Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School Boston, Massachusetts; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, Massachusetts; Center for Neurointestinal Health, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: kstaller@mgh.harvard.edu. 2. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 3. Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School Boston, Massachusetts; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, Massachusetts. 4. Center for Functional Gastrointestinal and Motility Disorders and Division of Gastroenterology and Hepatology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 5. Department of Urology and Obstetrics and Gynecology, Wake Forest University Medical Center, Winston-Salem, North Carolina. 6. Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School Boston, Massachusetts; Center for Neurointestinal Health, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
BACKGROUND & AIMS: Low estrogen levels can contribute to development of fecal incontinence (FI) in women after menopause by altering neuromuscular continence mechanisms. However, studies have produced conflicting results on the association between menopausal hormone therapy (MHT) and risk of FI. METHODS: We studied the association between MHT and risk of FI among 55,828 postmenopausal women (mean age, 73 years) who participated in the Nurses' Health Study, were enrolled since 2008, and with no report of FI. We defined incident FI as a report of at least 1 liquid or solid FI episode per month during 4 years of follow-up from self-administered, biennial questionnaires administered in 2010 and 2012. We used Cox proportional hazard models to calculate multivariate-adjusted hazard ratios and 95% confidence intervals (CIs) for FI risk in women receiving MHT, adjusting for potential confounding factors. RESULTS: During more than 185,000 person-years of follow-up, there were 6834 cases of incident FI. Compared with women who never used MHT, the multivariate hazard ratio for FI was 1.26 (95% CI, 1.18-1.34) for past users of MHT and 1.32 (95% CI, 1.20-1.45) for current users. The risk of FI increased with longer duration of MHT use (P trend ≤ .0001) and decreased with time since discontinuation. There was an increased risk of FI among women receiving MHT that contained a combination of estrogen and progestin (hazard ratio, 1.37; 95% CI, 1.10-1.70) compared with estrogen monotherapy. CONCLUSIONS: Current or past use of MHT was associated with a modestly increased risk of FI among postmenopausal women in the Nurses' Health Study. These results support a potential role for exogenous estrogens in the impairment of the fecal continence mechanism.
BACKGROUND & AIMS: Low estrogen levels can contribute to development of fecal incontinence (FI) in women after menopause by altering neuromuscular continence mechanisms. However, studies have produced conflicting results on the association between menopausal hormone therapy (MHT) and risk of FI. METHODS: We studied the association between MHT and risk of FI among 55,828 postmenopausal women (mean age, 73 years) who participated in the Nurses' Health Study, were enrolled since 2008, and with no report of FI. We defined incident FI as a report of at least 1 liquid or solid FI episode per month during 4 years of follow-up from self-administered, biennial questionnaires administered in 2010 and 2012. We used Cox proportional hazard models to calculate multivariate-adjusted hazard ratios and 95% confidence intervals (CIs) for FI risk in women receiving MHT, adjusting for potential confounding factors. RESULTS: During more than 185,000 person-years of follow-up, there were 6834 cases of incident FI. Compared with women who never used MHT, the multivariate hazard ratio for FI was 1.26 (95% CI, 1.18-1.34) for past users of MHT and 1.32 (95% CI, 1.20-1.45) for current users. The risk of FI increased with longer duration of MHT use (P trend ≤ .0001) and decreased with time since discontinuation. There was an increased risk of FI among women receiving MHT that contained a combination of estrogen and progestin (hazard ratio, 1.37; 95% CI, 1.10-1.70) compared with estrogen monotherapy. CONCLUSIONS: Current or past use of MHT was associated with a modestly increased risk of FI among postmenopausal women in the Nurses' Health Study. These results support a potential role for exogenous estrogens in the impairment of the fecal continence mechanism.
Authors: Adil E Bharucha; Alan R Zinsmeister; G Richard Locke; Barbara M Seide; Kimberly McKeon; Cathy D Schleck; L Joseph Melton Journal: Am J Gastroenterol Date: 2006-06 Impact factor: 10.864
Authors: Christina S Baik; Gary M Strauss; Frank E Speizer; Diane Feskanich Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-08-25 Impact factor: 4.254
Authors: David Parés; Mar Iglesias; Miguel Pera; Marta Pascual; Ariadna Torner; Teresa Baró; Sandra Alonso; Luis Grande Journal: Dis Colon Rectum Date: 2010-12 Impact factor: 4.585
Authors: Enrique Rey; Rok Seon Choung; Cathy D Schleck; Alan R Zinsmeister; G Richard Locke; Nicholas J Talley Journal: Am J Gastroenterol Date: 2009-10-20 Impact factor: 10.864
Authors: JoAnn E Manson; Judith Hsia; Karen C Johnson; Jacques E Rossouw; Annlouise R Assaf; Norman L Lasser; Maurizio Trevisan; Henry R Black; Susan R Heckbert; Robert Detrano; Ora L Strickland; Nathan D Wong; John R Crouse; Evan Stein; Mary Cushman Journal: N Engl J Med Date: 2003-08-07 Impact factor: 91.245
Authors: Adil E Bharucha; Charles H Knowles; Isabelle Mack; Allison Malcolm; Nicholas Oblizajek; Satish Rao; S Mark Scott; Andrea Shin; Paul Enck Journal: Nat Rev Dis Primers Date: 2022-08-10 Impact factor: 65.038
Authors: Kyle Staller; Mingyang Song; Francine Grodstein; Catherine A Matthews; William E Whitehead; Braden Kuo; Andrew T Chan; Mary K Townsend Journal: Clin Transl Gastroenterol Date: 2018-10-25 Impact factor: 4.488